RhoKing Glaucoma

Although its AR-12286 is not the most advanced Rho kinase inhibitor in the increasingly crowded glaucoma space, Aerie Pharmaceuticals Inc. believes the compound's potency and specificity will allow it to compete. Last week, the biotech announced top line data from a Phase IIa trial in which AR-12286 showed a favorable effect on intraocular pressure.

In the U.S. double-blind study in 88 patients, patients were given AR-12286 or sham eye drop once in the morning, once at night, or twice a day. Each dosing regime was administered for one week for a total of three weeks. Intraocular pressure (IOP) was measured for each dosing regime. No serious side effects were reported...